Elamin Elbasha
Overview
Explore the profile of Elamin Elbasha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yi Z, Owusu-Edusei K, Elbasha E
Infect Dis Ther
. 2024 Nov;
13(12):2597-2615.
PMID: 39514058
Introduction: Given the recent approval and recommendation of V116, a 21-valent pneumococcal conjugate vaccine (PCV), in the United States (US), we evaluated the cost-effectiveness of using V116 versus the 20-valent...
2.
Huang M, Weaver J, Elbasha E, Weiss T, Banniettis N, Feemster K, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340075
This study aimed to evaluate the cost-effectiveness of routine childhood immunization with the 20-valent pneumococcal conjugate vaccine (PCV20) in a four-dose regimen (3 + 1 schedule) versus the 15-valent PCV...
3.
Diakite I, Martins B, Owusu-Edusei K, Palmer C, Patterson-Lomba O, Gomez-Lievano A, et al.
Infect Dis Ther
. 2024 Apr;
13(5):965-990.
PMID: 38589763
Human papillomavirus (HPV) is a common sexually transmitted virus that can cause cervical cancer and other diseases. Dynamic transmission models (DTMs) have been developed to evaluate the health and economic...
4.
Odhiambo R, Chhatwal J, Ferrante S, Khoury A, Elbasha E
J Health Econ Outcomes Res
. 2023 Sep;
1(1):62-82.
PMID: 37664146
Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of...
5.
Huang M, Hu T, Weaver J, Owusu-Edusei K, Elbasha E
Vaccines (Basel)
. 2023 Jan;
11(1).
PMID: 36679980
This study evaluated the clinical and economic impact of routine pediatric vaccination with the 15-valent pneumococcal conjugate vaccine (PCV15, V114) compared with the 13-valent PCV (PCV13) from a societal perspective...
6.
Sharomi O, Xausa I, Nachbar R, Pillsbury M, Matthews I, Petigara T, et al.
Vaccines (Basel)
. 2022 Sep;
10(9).
PMID: 36146493
Universal varicella vaccination (UVV) in England and Wales has been hindered by its potential impact on exogenous boosting and increase in herpes zoster (HZ) incidence. We projected the impact of...
7.
Daniels V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, Saah A, Luxembourg A, et al.
Vaccine
. 2022 Mar;
40(14):2173-2183.
PMID: 35232593
Although no human papillomavirus (HPV) vaccine is indicated for single-dose administration, some observational evidence suggests that a 1-dose regimen might reduce HPV infection risk to that achieved with 2 doses....
8.
Daniels V, Prabhu V, Palmer C, Samant S, Kothari S, Roberts C, et al.
Hum Vaccin Immunother
. 2021 Jan;
17(7):1943-1951.
PMID: 33427033
The Advisory Committee on Immunization Practices (ACIP) recommended catch-up 9-valent Human Papillomavirus (HPV) vaccination through age 26 years, and shared clinical decision-making for adults aged 27-45 years, compared with catch-up...
9.
Majed L, Bresse X, El Mouaddin N, Schmidt A, Daniels V, Pavelyev A, et al.
Vaccine
. 2020 Dec;
39(2):438-446.
PMID: 33261895
Objectives: In France, 9-valent HPV vaccination is recommended routinely for 11-14-years-old girls and as catch-up for 15-19-years-old girls. Recently, recommendation for gender-neutral vaccination (GNV) has been approved. The objectives of...
10.
Prabhu V, Dubberke E, Dorr M, Elbasha E, Cossrow N, Jiang Y, et al.
Clin Infect Dis
. 2017 Nov;
66(3):355-362.
PMID: 29106516
Background: Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab, administered concurrently with antibiotics directed against C. difficile (standard of care [SoC]), has been shown...